marijuana stocks

Affinor Growers, Inc. (RSSFF)

Other OTC

0.13 Up 0.00(3.47%) 1:36PM EST
Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Nov 30, 2014 Aug 31, 2014 May 31, 2014 Feb 28, 2014
Total Revenue 41   43   –   –  
Cost of Revenue
Gross Profit 41   43   –   –  
Operating Expenses
Research Development
Selling General and Administrative 1,145 1,342 7,187 95
Non Recurring
Others 8 5
Total Operating Expenses
Operating Income or Loss (1,113) (1,304) (7,298) (95)
Income from Continuing Operations
Total Other Income/Expenses Net (12) 21 9 (9)
Earnings Before Interest And Taxes (1,125) (1,283) (7,290) (104)
Interest Expense 0 (1)
Income Before Tax (1,125) (1,283) (7,290) (104)
Income Tax Expense (6) 2
Minority Interest
Net Income From Continuing Ops (1,125) (1,283) (7,283) (105)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (1,125) (1,283) (7,283) (105)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (1,125) (1,283) (7,283) (105)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

 Sundial Growers Inc. (SNDL) Announces New Board Member

Sundial Announces New Board Member  Sundial Growers Inc. (Nasdaq: SNDL) (“Sundial”) and…

Namaste Technologies Inc. (NXTTF) & Emerald Health Therapeutics (EMHTF) Announce Letter of Intent for International Partnership

Emerald Health Therapeutics and Namaste Technologies Announce Letter of Intent for International…

InMed Pharmaceuticals Inc. (IMLFF) Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755…

$ATTBF Investor Update for Q2 2015

Abattis Bioceuticals Investor Update for Q2 2015  Abattis Bioceuticals Corp. (the “Company”…